Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
24 participants
INTERVENTIONAL
2025-11-25
2026-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Saline will act as a control and will be intradermally injected.
Control Saline
Saline solution will be the placebo control. The active is diluted with saline so this is an appropriate control.
Active-Secretome
Autologous Hair follicle Derived Secretome
Autologous Hair Follicle-Derived Secretome
This interventional product is a secretome derived from the stem cells that reside in the hair follicle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Hair Follicle-Derived Secretome
This interventional product is a secretome derived from the stem cells that reside in the hair follicle.
Control Saline
Saline solution will be the placebo control. The active is diluted with saline so this is an appropriate control.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age: ≥30 and ≤ 70 at the time of consent.
3. Fitzpatrick skin types I-V
4. Moderate to very severe facial aging according to the SASSQ for the categories of elasticity, wrinkles, and skin roughness.
5. Willing to refrain from cosmetic procedures throughout the study period (i.e. laser treatments, chemical peels, microneedling, dermal filler injections, neuromodulator injections, etc.)
6. Willing to use study support products as directed and will not introduce any new skin care or makeup products throughout the study period. Subjects will be provided with a Skincare Kit: Cetaphil Gentle Skin Cleanser 20 oz, Cetaphil Daily Hydrating Lotion 3 oz, Cetaphil Sheer Mineral Sunscreen Broad Spectrum SPF 50 1.7 oz. Two of each will be provided with application instructions.
7. Male subjects with facial hair must be willing to shave the morning of their treatments/follow-up visits.
8. Willing to minimize sun/ultraviolet light exposure for the duration of the study, including all of the following: applying sunscreen daily, at least 15 minutes before going outside; wearing sun-protective clothing (e.g., a hat, sunglasses) when outdoors; reapplying sunscreen every 2 hours during outdoor activities; avoiding tanning bed/tanning product use.
1. Male or Female
2. Age: ≥30 and ≤ 70 at the time of consent.
3. Fitzpatrick skin types I-V
4. Moderate to very severe facial aging according to the SASSQ for the categories of elasticity, wrinkles, and skin roughness.
5. Willing to refrain from cosmetic procedures throughout the study period (i.e. laser treatments, chemical peels, microneedling, dermal filler injections, neuromodulator injections, etc.)
6. Willing to use study support products as directed and will not introduce any new skin care or makeup products throughout the study period. Subjects will be provided with a Skincare Kit: Cetaphil Gentle Skin Cleanser 20 oz, Cetaphil Daily Hydrating Lotion 3 oz, Cetaphil Sheer Mineral Sunscreen Broad Spectrum SPF 50 1.7 oz. Two of each will be provided with application instructions.
7. Male subjects with facial hair must be willing to shave the morning of their treatments/follow-up visits.
8. Willing to minimize sun/ultraviolet light exposure for the duration of the study, including all of the following: applying sunscreen daily, at least 15 minutes before going outside; wearing sun-protective clothing (e.g., a hat, sunglasses) when outdoors; reapplying sunscreen every 2 hours during outdoor activities; avoiding tanning bed/tanning product use.
9. Competent and willing to provide written, informed consent to participate in all study activities
10. Willing and able to tolerate multiple injections and attend all study visits
11. Negative urine pregnancy test result at the time of screening (if applicable)
12. For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
Exclusion Criteria
2. Dermatologic diseases or conditions (e.g. atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, wounds, infections, irritation, sunburn, windburn, etc.) in the treatment area that could interfere with the study, in the opinion of the Investigator
3. History of keloid formation, hypertrophic scarring, or abnormal/delayed wound healing
4. Previous medical aesthetic rejuvenation treatments on the face, such as chemical peel, dermabrasion, non-ablative or ablative resurfacing procedure, or face-lift with laser or other devices, up to 3 months prior to baseline photography
5. Treatment with neuromodulators in crow's feet, glabellar region, or frontalis muscles within 4 months prior to baseline photography
6. Treatment with dermal fillers, collagen stimulators, fat injections or permanent fillers within the past 6 months prior to baseline photography.
7. Patients using other anti-aging treatments/procedures/systemic medications or injections administered/prescribed by a medical professional before starting the study, if the investigator believes they will confound the results. Consulting with Sponsor is encouraged.
8. Heavy smoker (\>1 pack of cigarettes a day)
9. Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area within 6 months prior to baseline photography
10. Currently be taking isotretinoin (Accutane).
11. Subjects on an immunosuppressant or have an autoimmune condition (except stable, controlled Hashimoto's thyroiditis)
12. Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction, etc.) during the 12-month period prior to baseline photography
13. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
14. Severe active infection (e.g. HIV, HepB or C, UTI, etc.)
15. Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers as long as basal cell was not on the face)
16. History of systemic chemotherapy or radiation within the last 5 years
17. Continuous/daily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.
18. Anticipated pregnancy or trying to become pregnant in the next year
19. Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, endoxaban and betrixaban; warfarin/coumarins). Low dose aspirin and omega-3 supplements allowed.
20. Any other criterion that based on the clinical judgment of the investigator may place the subject at risk or confound study results
21. Unable or unwilling to comply with the requirements (i.e. removal of jewelry, makeup, facial hair) of the study protocol in the opinion of the Investigator
22. Subject has any disorder that may prevent compliance, such as a history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the evaluator's opinion, interfere with the study.
\-
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acorn Biolabs Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Steve Yoelin, MD
Newport Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Margaret Xu
Role: primary
Steve Yoelin, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACN-301
Identifier Type: -
Identifier Source: org_study_id